Inventories

12 Months Ended

Nov. 30, 2023

Classes of current inventories [abstract]

9.	Inventories




	2023		2022


Raw materials	$	2,262	$	2,583

Work in progress		1,708		5,815

Finished goods		2,096		11,290


	$	6,066	$	19,688

In fiscal 2023, inventories of $18,540 (2022

$19,587) were recognized as an expense and included in cost of goods sold.

In the second quarter of 2023, inventories for an amount of $3,295 was returned to TaiMed. and accounts payable was reduced by a total amount of

€

3,179 ($3,399).

In fiscal 2023, an inventory provision of

220

(2022 –

nil

)

was recognized pending marketing approval of the F8 formulation of tesamorelin and recorded in cost of sales.

Inventories were written down to net realizable value by an amount of $2,137 in 2022, which was recorded in cost of sales. Included in the 2022 write-down is a provision of $1,477 on the F8 formulation and $339 on material for the pen in development to be used in conjunction with the F8 formulation, and $252 on expired raw material. The 2022 write-down also includes a provision of $69 on excess stock of

EGRIFTA

as a result of the Company’s decision to withdraw the product from the market in Canada.